Pathstone Holdings’s Integra LifeSciences IART Stock Holding History

Pathstone Holdings’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+12,818	New	+$179K	﹤0.01%	2181
2025 Q2	–	Sell	-21,273	Closed	-$468K	–	2251
2025 Q1	$468K	Buy	21,273 +3,349	+19%	+$78.7K	﹤0.01%	1746
2024 Q4	$407K	Buy	17,924 +4,571	+34%	+$99.8K	﹤0.01%	1819
2024 Q3	$243K	Sell	13,353 -26,395	-66%	-$612K	﹤0.01%	2084
2024 Q2	$1.16M	Hold	39,748	–	–	0.01%	1241
2024 Q1	$1.41M	Buy	39,748 +24,794	+166%	+$992K	0.01%	1073
2023 Q4	$651K	Buy	+14,954	New	+$589K	﹤0.01%	1347

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Pathstone Holdings's IART Position: Q2 2026 in Review

Pathstone Holdings opened a new position in Integra LifeSciences (IART) in Q2 2026: 12,818 shares worth $230K. The stake represents ﹤0.01% of the portfolio and ranks #2181 among its holdings. This is a return to the name: Pathstone Holdings previously reported a position in IART as recently as Q1 2025.

Pathstone Holdings first reported a position in IART in Q4 2023 and has held it in 7 quarters since. The position peaked at $1.41M in Q1 2024. 213 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Pathstone Holdings held 12,818 shares of Integra LifeSciences worth $230K as of Q2 2026.
Integra LifeSciences was a new Pathstone Holdings position in Q2 2026.
Integra LifeSciences made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2181 holding.
Pathstone Holdings first reported a position in Integra LifeSciences in Q4 2023 and has held it in 7 quarters since.
Pathstone Holdings's Integra LifeSciences position peaked at $1.41M in Q1 2024.
213 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.